Asia-Pacific Synthetic Biology Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

The Asia-Pacific synthetic biology market is expected to grow at a CAGR of 35.0% during the forecast period. The initiatives by major economies in the field of synthetic biology are one of the factors that is promoting technological innovations in the Asia-Pacific region. China is investing in the synthetic biology driven by a coordinated national strategy under state sponsored programs. This result in growth in number of journal publications, for instance, in 2013 out of total papers published on synthetic biology 10% were from China.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-synthetic-biology-market

The other countries such as India, Japan and South Korea are rapidly developing vibrant synthetic biology communities, supported by national institutes on synthetic biology. This institutes generating research outputs that significantly contributing to the advancements in the synthetic biology. In October 2017, Australia and China symposium on synthetic biology was held to facilitate stronger collaborative ties between two countries by making Australia-China Science and Research Fund (ACSRF).

The Asia-Pacific synthetic biology market is segmented on the basis of product, technology, and applications. Based on the product, the market is segmented into enabling product, core product, and enabled product. Core product includes synthetic genes, synthetic cells, synthetic DNA, chassis organisms and xeno nucleic acid (XNA), and are expected to hold a significant share in the market owing to extensive use of core products in R&D. Based on technology, the market is segmented into, and gene synthesis & sequencing, genome engineering, bioinformatics, and others. Based on application, the market is segmented into medical application, industrial application, food & agriculture, and environmental applications.

Moreover, the study of the report covers the competitive analysis of various players operating in the Asia-Pacific synthetic biology market. Some of the key players in the Asia-Pacific synthetic biology market include Twist Bioscience Corp., Merck KGaA, GenScript Biotech Corp., Thermo Fisher Scientific Inc., Amyris Inc., Codexis Inc, Ginkgo Bioworks, and many others.

A full report of Asia-Pacific Synthetic Biology Market available @ https://www.omrglobal.com/industry-reports/asia-pacific-synthetic-biology-market

Asia-Pacific Synthetic Biology Market Segmentation

By Product

Enabling Product
Core Product
Enabled Product

By Technology

Gene Synthesis & Sequencing
Genome Engineering
Bioinformatics
Others

By Application

Medical Application
Industrial Application
Food & Agriculture
Environmental Application

Regional Analysis

China
India
Japan
Rest of Asia-Pacific

Company Profiles

Autolus Therapeutics PLC
Butamax Advanced Biofuels LLC
Desktop Genetics, Ltd.
I. du Pont de Nemours and Co.
GenScript Biotech Corp.
Ginkgo Bioworks (The Organism Co)
Integrated DNA Technologies, Inc.
LGC, Ltd.
Merck KGaA
Thermo Fisher Scientific, Inc.
Twist Bioscience Corp.

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.